sanofi cost cutting Pages on BioPortfolio:

BioPortfolio - sanofi cost cutting
Recent Search Terms used to find this page: sanofi Sanofi-Synthelabo | synthelabo | sanofi cost cutting | Sanofi-Synthelabo Research | Institut Synthelabo . ...
http://www.bioportfolio.com/search/sanofi_cost_cutting.html...

BioPortfolio - sanofi-synthelabo
sanofi-synthelabo - Entry on Bioportfolio's Biocorporate Database. ... sanofi cost cutting | Sanofi-Synthelabo Research | Institut Synthelabo SANOFI | . ...
http://www.bioportfolio.com/biocorporate/9150-sanofi-synthel...

Progress in the treatment of peripheral arterial disease (PAD)
Sanofi-Aventis's NV1FGF is the most promising agent in development and is ... The agreement between Sanofi-Aventis and Vical allows Sanofi-Aventis to use ...
http://www.bioportfolio.com/news/DailyUpdates_72.htm...

BIOPROGRESS PLC ANNOUNCES ACQUISITION, JOINT VENTURE, FUND RAISING ...
31 Dec 2005 ... As part of the cost reduction initiatives and to reflect the changes to the ... BioProgress aims to provide a cost effective and animal-free ...
http://www.bioportfolio.com/biotech_news/BioProgress_1.htm...

Inhibitors of Gas6 as improved anti-thrombosis candidates
Sanofi-Synthelabo DuPont Mitsubishi-Tokyo. Thrombin inhibitors .... for life scientists we aim to help industry identify cutting edge drug discovery options ...
http://www.bioportfolio.com/LeadDiscovery/0246.htm...

BioPortfolio Limited Datamonitor
Governments and payers across the seven major markets are implementing cost-cutting initiatives to combat escalating healthcare costs, putting even greater ...
http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor.htm...

Advances in the Treatment of Cardiovascular Diseases
The PCI procedure could include stent implantation, balloon and cutting balloon ... Clopidogrel (Plavix®, Bristol-Myers Squibb/Sanofi Synthelabo) ...
http://www.bioportfolio.com/reports/DMD_card.htm...

Management Reports
The Market for Restriction Enzymes Cutting Out Your Competition ..... products to dampen the impact of patent expiries and cost containment initiatives ...
http://www.bioportfolio.com/reports/...

HMP-12 an adrenoceptor antagonist for the treatment of male and ...
This cost-effective approach is believed to allow for a relatively .... life scientists we aim to help industry identify cutting edge drug discovery options ...
http://www.bioportfolio.com/LeadDiscovery/mdi002.htm...

Biotechnology News share price delhaiz. zentiva. 332153. lrlcy ...
UPDATE 1-Sanofi-Aventis pays $544 mln for Primary Health unit (Adds CEO comment, share price) ... dollar and cost cutting efforts, and beating forecasts. ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=e...

Results from other life science and pharmaceutical sites:

Sanofi takeover jeopardizes Aventis biotech deals - Nature ...
And judging from comments made by Sanofi's CEO Jean-Francois Dehecq, Aventis' heavily biotech-oriented R&D effort is the number-one target for cost cutting ...
http://www.nature.com/nbt/journal/v22/n6/full/nbt0604-639.ht...

Total - Corporate Web Site - Press releases - Feb. 03, 00 - Elf ...
Gain on dilution of Sanofi (+1057million euros) and corporate expenses (-216 ... Continued cost cutting and self-help measures amounted to a record 210 ...
http://www.total.com/en/press/press_releases/pr_2000/000203_...

: Article : Nature Reviews Drug Discovery
Investors reacted well to Pfizer's plans, but some analysts remained unconvinced, as Pfizer did not disclose details of how the cost-cutting would be ...
http://www.nature.com/nrd/journal/v4/n5/full/nrd1742.html...

Cost cutting boosts Novartis Q1 profit
But it benefited from dollar weakness and a cost-cutting program at its drugs ... large-cap drugmakers such as GlaxoSmithKline Plc and Sanofi-Aventis SA ...
http://www.canada.com/montrealgazette/news/business/story.ht...

PDUFA IV Meetings – Technical Discussions with Regulated Industry ...
2 hours, FDA PDUFA IV cost estimate, Malcolm Bertoni, FDA Armando Oliva, FDA Mark Gray, FDA Len Wilson, FDA Margo Burnette, FDA Peter Loupos, sanofi aventis ...
http://www.fda.gov/oc/pdufa4/itimsubgrp.html...

Prior Authorization of Newer Insomnia Medications in Managed Care ...
2Health Outcomes, Sanofi Aventis, Bridgewater, NJ .... and patients may perceive prior authorization as a cost-cutting measure at the expense of the most ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=19...

Investor Information: Press Release: ImmunoGen, Inc.
Our other collaborators - sanofi-aventis, Biogen Idec and Biotest - also have had notable product achievements. We recently unveiled another cutting-edge ...
http://www.immunogen.com/wt/redirect/pr_1218139651...

Aucun titre de diapositive
Cutting edge Research technologies: - Genomics - Combinatorial Chemistry - High throughput screening. R&D : The new portfolio. Sanofi-Synthélabo ...
http://www.total.com/static/en/medias/topic426/Sanofi_199812...

...

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright 1997-2008 - BioPortfolio Limited.